Shares of Tango Therapeutics TNGX surged 53% on Monday after the company reported encouraging initial data from an ongoing phase I/II study evaluating combination treatments involving its investigational drug, vopimetostat.
The study is assessing vopimetostat plus one of Revolution Medicines’ RVMD experimental RAS inhibitors — daraxonrasib or zoldonrasib — in previously treated patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC).
The strongest results were reported from the vopimetostat-daraxonrasib arm. Among 12 evaluable patients, the combination achieved an objective response rate (ORR) of 92%, with a disease control rate (DCR) of 100% and a six-month progression-free survival (PFS) rate of 90%. In contrast, the vopimetostat-zoldonrasib combination achieved a 52% ORR across 27 evaluable patients, a DCR of 96% and a six-month PFS rate of 74%. Both combinations were generally well tolerated.
The data drew significant attention from investors and analysts, many of whom were particularly impressed by the vopimetostat-daraxonrasib results. Investors also welcomed the company's decision to advance this combination into late-stage development for first-line MTAP-deleted pancreatic cancer.
Management believes the findings support the broader strategy of combining PRMT5 inhibition with RAS-targeted therapies and reinforce the potential for a chemotherapy-free treatment option in patients with MTAP-deleted pancreatic cancer.
TNGX Stock’s Price Performance
Year to date, the company’s shares have skyrocketed 249% against the industry’s 3% fall.
Image Source: Zacks Investment Research
More on TNGX’s Vopimetostat
The drug is a selective PRMT5 inhibitor designed to target cancers harboring MTAP deletions, a genetic alteration found across multiple tumor types, including pancreatic cancer. Apart from the above study, vopimetostat is also being tested as a monotherapy in a phase I/II study across MTAP-deleted solid tumors. Data from this study is expected later this year.
In March, Tango Therapeutics entered into a clinical trial collaboration and supply agreement with Erasca ERAS. Under the agreement, the companies will evaluate vopimetostat in combination with ERAS' pan-RAS molecular glue, ERAS-0015, in patients with MTAP-deleted RAS-mutant cancers. Tango plans to initiate a phase I/II study before year-end, further expanding the development opportunities for vopimetostat.
Tango Therapeutics, Inc. Price
Tango Therapeutics, Inc. price | Tango Therapeutics, Inc. Quote
TNGX’s Zacks Rank
Tango Therapeutics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Revolution Medicines, Inc. (RVMD): Free Stock Analysis Report
Erasca, Inc. (ERAS): Free Stock Analysis Report
Tango Therapeutics, Inc. (TNGX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).